Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01904903
Recruitment Status : Active, not recruiting
First Posted : July 22, 2013
Last Update Posted : December 21, 2018
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Washington Hospital Center

Brief Summary:

HER2 positive breast cancer cells have more HER2 receptor (a protein on the surface of cells) than normal breast cells. Approximately 30% of patients with breast cancer have HER2 positive breast cancer. Before HER2 targeted therapies (i.e. treatments that directly block the receptor HER2) were developed, patients with HER2 positive breast cancer had a very aggressive form of disease. With the use of trastuzumab, an anticancer drug that directly targets the receptor HER2, and more recently, pertuzumab and ado-trastuzumab emtansine, patients are able to live longer and have better control of their cancer.

Unfortunately the use of HER2 targeted therapies can increase the risk of heart problems and for this reason these treatments were only studied and approved for patients with normal heart function.

In this study we plan to give HER2 targeted therapies to patients with HER2 positive breast cancer and mildly decreased heart function along with concomitant evaluation by a heart doctor (called cardiologist) and appropriate medications to strengthen the heart. We will do frequent monitoring of the heart function with a test called echocardiogram that will give us a detailed "picture" of the heart. We will also draw blood along with routine blood tests to try to understand why some patients develop heart problems and others do not. The study will take a maximum of 12 months and patients will be monitored for 6 additional months.

We hypothesize that it is safe to administer HER2 targeted therapies to patients with breast cancer and mildly decreased heart function, i.e. LVEF between 40 and 50%, while on appropriate heart medications.


Condition or disease Intervention/treatment Phase
HER2 Positive Breast Cancer Left Ventricular Function Systolic Dysfunction Drug: Trastuzumab Drug: Pertuzumab Drug: Ado Trastuzumab Emtansine Phase 2

Detailed Description:

Title: A pilot study evaluating the cardiac safety of HER2 targeted therapy (non-lapatinib) in patients with HER2 positive breast cancer and reduced left ventricular function Phase: Pilot study Study Duration: 4 years with up to 5 additional years of follow up Study Center(s): 3 centers will be participating: MedStar Washington Hospital Center (MWHC), MedStar Georgetown University Hospital (MGUH) and Memorial Sloan Kettering Cancer Center (MSKCC) Primary Objective: To evaluate the cardiac safety of HER2 targeted therapy (non-lapatinib) in patients with HER2 positive breast cancer and reduced left ventricular ejection fraction (LVEF) when given concomitantly with cardiac treatment.

Secondary Objectives:

  • To evaluate time to development of cardiac event or asymptomatic worsening of cardiac function
  • Absolute changes in LVEF
  • Delays in HER2 therapy attributed to cardiac causes
  • Correlations between echocardiographic myocardial strain
  • cTnI and hs-cTnT at baseline and over time with cardiac events and asymptomatic worsening of cardiac function Sample size: 30 patients

Diagnosis and Main Inclusion Criteria:

  • HER2 positive breast cancer, stage I-IV.
  • Mildly decreased cardiac function (LVEF between 40 and 49%) prior to or while receiving non-lapatinib HER2 targeted therapy

Cardiac Intervention:

- Beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses

Oncology study Products, Doses, Routes, Regimens:

  • Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.
  • Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.
  • Ado-trastuzumab emtansine: 3.6mg/kg IV every three weeks. Note: both trastuzumab and pertuzumab may be administered alone or in combination with other systemic or radiation therapy.

Duration of drug administration: Maximum of 12 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function
Actual Study Start Date : October 2013
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
HER2 therapies, cardiac medications

Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses

Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:

  • Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.
  • Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.
  • Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks.
Drug: Trastuzumab
HER2 therapy
Other Name: Herceptin

Drug: Pertuzumab
HER2 therapy
Other Name: Perjeta

Drug: Ado Trastuzumab Emtansine
HER2 therapy
Other Name: Kadcyla




Primary Outcome Measures :
  1. Proportion of patients who complete planned oncologic therapy without the development of a cardiac event or asymptomatic worsening of cardiac function. [ Time Frame: Up to 18 months. ]

    Cardiac events are defined as any of the following:

    • Presence of symptoms attributable to heart failure as confirmed by a cardiologist
    • Cardiac arrhythmia requiring pharmacological or electrical treatment
    • Myocardial infarction
    • Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure

    Asymptomatic worsening of cardiac function defined as:

    - Asymptomatic decline in LVEF > 10% points from baseline and/or EF < 35% corroborated by a confirmatory echocardiogram in 2-4 weeks

    Planned oncologic therapy is defined as:

    • In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved when a total of 1 year is completed.
    • In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death.


Secondary Outcome Measures :
  1. Median time to development of an event defined as cardiac event or asymptomatic worsening of left ventricular dysfunction, among patients who developed one event. [ Time Frame: Up to 18 months. ]
    Descriptive exploratory analysis

  2. Absolute changes in LVEF during HER2 targeted therapy [ Time Frame: Up to 18 months. ]
    Descriptive exploratory analysis

  3. HER2 therapy holds attributed to proportion of patients with symptomatic or asymptomatic cardiotoxicity. [ Time Frame: Up to 12 months. ]
    Hold is defined as any delay or discontinuation of HER2 targeted therapy due to cardiac toxicity. One cycle of HER2 targeted therapy will be considered 3 weeks. One therapy hold will be defined as any 3-week HER2 targeted therapy missed dose or 1/3 if one weekly trastuzumab dose. For patients who had a hold and resumed HER2 targeted therapy, duration of treatment hold will be described.

  4. Correlation of global longitudinal myocardial strain with cardiac events and asymptomatic worsening of cardiac function [ Time Frame: Up to 18 months. ]
    Descriptive exploratory analysis

  5. Correlation of standard cardiac troponin I and highly sensitive cardiac troponin T with cardiac events and asymptomatic worsening of cardiac function [ Time Frame: Up to 18 months. ]
    Descriptive exploratory analysis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female or male patient diagnosed with stage I-IV breast cancer
  • HER2 positive breast cancer, defined by immunohistochemical staining for HER2 protein of 3+ intensity and/or amplification of the HER2 gene on fluorescence in situ hybridization (FISH) ≥ 2.0 on breast specimen or biopsy of a metastatic site
  • LVEF < 50% and ≥ 40% documented in echocardiogram done within the last 30 days
  • HER2 therapy naïve or currently receiving non-lapatinib HER2 targeted therapy
  • Patient receiving or planning to receive trastuzumab, trastuzumab with pertuzumab or ado-trastuzumab emtansine, for at least 3 months, alone or in combination with other systemic treatment or radiation
  • Age ≥ 18 years
  • Patient is willing and able to comply with protocol required assessments and procedures

Exclusion Criteria:

  • Previous hospitalization due to documented heart failure in the last 12 months
  • Current signs or symptoms of heart failure or ischemia
  • History of arrhythmia requiring pharmacological or electrical treatment
  • Concomitant use of anthracyclines or use of anthracyclines in the last 50 days
  • Pregnant or lactating patients. Patients of childbearing potential must implement contraceptive measures during study treatment and for 7 months after last dose of treatment drug and must have negative urine or serum pregnancy test within 7 days prior to registration.
  • History of significant neurologic or psychiatric disorders including psychotic disorders or dementia that would prohibit the understanding and giving of informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904903


Locations
Layout table for location information
United States, District of Columbia
Washington Cancer Institute at MedStar Washington Hospital Center
Washington, District of Columbia, United States, 20010
MedStar Georgetown University Hospital
Washington, District of Columbia, United States, 20057
Sponsors and Collaborators
Washington Hospital Center
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Sandra M Swain, MD Washington Cancer Institute at MedStar Washington Hospital Center

Layout table for additonal information
Responsible Party: Washington Hospital Center
ClinicalTrials.gov Identifier: NCT01904903     History of Changes
Other Study ID Numbers: ML 28685
First Posted: July 22, 2013    Key Record Dates
Last Update Posted: December 21, 2018
Last Verified: December 2018

Keywords provided by Washington Hospital Center:
Breast Cancer HER2 Positive
Cardiac Safety

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Pertuzumab
Ado-trastuzumab emtansine
Maytansine
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action